Yiou Health reported in August 10 that the innovative CRO platform drug research institute recently completed two rounds of financing, C+ and D, with a total amount exceeding 600 million yuan. Among them, the D round was led by ggv Capital and Yuan Jing Capital, and the old shareholders Jingwei China and Zhongding Capital continued to increase their holdings; The C+ Round was jointly led by Sequoia China and Zhongding Capital, followed by old shareholders such as Jingwei China, Yuan Jing Capital and Sheng Yuan Capital.
The financing funds will continue to be used to strengthen the standardization and systematization of drug research and development infrastructure, promote the clinical research technology platform, and open it to the industry and enjoy it. It is reported that the time interval between the two rounds of financing is no more than 8 months.
Established on 20 15 and 12, the institute of pharmaceutical research is a CRO technology platform dedicated to providing innovative drug research and development services for pharmaceutical enterprises. The Institute of Drug Research focuses on solving two problems, making the cycle of drug research and development shorter and the cost lower. The Institute of Pharmaceutical Research has established a standardized and streamlined pharmaceutical R&D service model. Compared with the traditional model, the overall R&D cycle is shortened by 20%, and the average cost is saved 15%. Behind the improvement of efficiency, the Institute of Drug Research covers one-stop services such as CRO, SMO, quick start-up of the center, patient recruitment, manpower distribution and intelligent data service.
2065438+In April 2009, the Institute of Pharmacology released the experiment. Clinical research portal platform Link. The platform can intelligently match participants in drug research and development, reduce communication costs and improve research and development efficiency. Today, the Institute of Pharmaceutical Research has successfully completed the closed-loop of multiple core advantages such as products, data, technology and talent innovation, and is open and enjoys its trial. Link technology platform to better serve practitioners, researchers, patients, pharmaceutical companies and hospitals.
Sun Meilin once said in an interview that in the past year, the business of the Institute of Pharmaceutical Research has more than tripled, and it has maintained in-depth business cooperation with hospitals above 1500+. Among them, the number of hospitals that have settled in the trial. There are more than 500+ link platforms and more than 65,438+pharmaceutical enterprises. Platform products cover more than 95% of practitioners.
In 20 19, there were only clinical trials of innovative drugs 1 one, and CDE accepted 302 varieties, an increase of 26.4% compared with 20 18. Wu, executive director of ggv Capital, and partners of GGV Capital both expressed optimistic growth space.
"We believe that the reform direction of CRO 2.0 represented by Pharmaceutical Research Institute can bring win-win results to experimental participants such as pharmaceutical companies, hospitals, subjects and regulatory agencies." Wu said to: